Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Differentiated Thyroid Cancer Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

8 recruiting trials for Differentiated Thyroid Cancer. Eligibility criteria explained in plain English.

TrialFinderData lists 8 Differentiated Thyroid Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 80% (4 studies); the largest phase groups are Phase 2: 4, Phase 1: 1.

Research is led by Children's Hospital of Philadelphia (3), Istituti Clinici Scientifici Maugeri SpA (1), Fudan University (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is 131I therapy (radiation, 2 trials), followed by Pembrolizumab, Larotrectinib monotherapy.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
8
Total Trials
8
Recruiting Now
0
Phase 3 Trials
6
Sponsors

Track Differentiated Thyroid Cancer trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT05852223

Pembrolizumab in High-risk Thyroid Cancer

This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 251 location
RECRUITINGPhase 2NCT05783323

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical...

Sponsor: Children's Hospital of PhiladelphiaEnrolling: 135 locations
RECRUITINGPhase 2NCT05989425

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer....

Sponsor: Fudan UniversityEnrolling: 321 location
RECRUITINGNCT05604963

Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers

This is a multi-centre, randomised, non-inferiority, phase III study in patients with low risk differentiated thyroid cancer. Patients will be identified via oncology...

Sponsor: University College, LondonEnrolling: 45620 locations
RECRUITINGPhase 2NCT06458036

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical...

Sponsor: Children's Hospital of PhiladelphiaEnrolling: 134 locations
RECRUITINGNCT05024929

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently...

Sponsor: Children's Hospital of PhiladelphiaEnrolling: 329 locations
RECRUITINGNCT07436455

F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy,...

Sponsor: Ankara UniversityEnrolling: 502 locations
RECRUITINGPhase 1NCT05538130

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced...

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with...

Sponsor: PfizerEnrolling: 12420 locations

Frequently Asked Questions

There are currently 8 clinical trials for Differentiated Thyroid Cancer, with 8 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Differentiated Thyroid Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Differentiated Thyroid Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.